spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DGF 

 HSMN NewsFeed - 27 Oct 2022
Geistlich Pharma North America, Inc. Acquires Lynch Biologics, LLC, a Biologics and Tissue Engineering Company
Regenerative Medicine Surgery Mergers & Acquisitions
 HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jan 2022
Blueprint Medicines' AYVAKYT(R) (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jul 2021
SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Nov 2020
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK(R) (Ripretinib) in a Multi-Regional Agreement
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 25 Sep 2020
Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 May 2020
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2020
PANTHERx(R) Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2018
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
Devices Wound Care Mergers & Acquisitions
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 12 Dec 2016
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista(R) in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2016
CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 2 May 2016
Graybug Vision Announces $44.5 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 5 Jan 2016
Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Jul 2015
Ophthotech Announces New Senior Leadership Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2014
Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 1 Mar 2013
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
Devices Orthopaedic Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2012
Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine Businesses
Devices Orthopaedic Mergers & Acquisitions
 HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2012
Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2012
Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen(TM) in South Korea
Devices Wound Care Distribution
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2011
Healthpoint Biotherapeutics Acquires Regranex(R) Gel
Biopharmaceuticals Wound Care Acquisitions
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Mar 2011
Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
Devices Wound Care Regenerative Medicine
 HSMN NewsFeed - 28 Feb 2011
Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2011
Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2011
BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment(TM) Bone Graft
Devices Regenerative Medicine Orthopaedic FDA
 HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Biopharmaceuticals
 HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Biopharmaceuticals
 HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2010
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2009
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 15 Dec 2009
Ophthotech Raises $30 Million in Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2009
Positive Findings from Excellarate(TM) Phase 1/2 Clinical Study Published in Journal of Wound Repair and Regeneration
Devices Biopharmaceuticals Wound Care
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2009
Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
Devices Regenerative Medicine Wound Care
 HSMN NewsFeed - 28 Jul 2009
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Regenerative Medicine Wound Care
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 May 2009
Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2009
Cardium's InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapy's Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
Devices Neurosurgery
 HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Mar 2009
Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Devices Urology Oncology
 HSMN NewsFeed - 16 Dec 2008
Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
Devices Urology
 HSMN NewsFeed - 15 Dec 2008
Cardium's InnerCool Awarded U.S. Supplier Agreement With Novation LLC
Devices Group Purchasing
 HSMN NewsFeed - 11 Nov 2008
Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
Devices Urology
 HSMN NewsFeed - 20 Oct 2008
Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System
Devices FDA
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jul 2008
Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
Devices Regulatory
 HSMN NewsFeed - 8 Jul 2008
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 21 May 2008
Aethlon Medical Announces Cancer Treatment License
Devices Licensing
 HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2008
Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University
Devices Neurosurgery
 HSMN NewsFeed - 21 Apr 2008
BioMimetic Therapeutics Receives Written Communication from FDA Confirming Status of Ongoing Pivotal Trial for GEM OS1
Devices Orthopaedic
 HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Apr 2008
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
Devices Cardiology
 HSMN NewsFeed - 27 Mar 2008
BioMimetic Therapeutics Addresses FDA Communication on Regranex Safety Review
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 19 Mar 2008
Cardium's InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
Devices Distribution
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2007
BioMimetic Therapeutics Reports Positive Clinical Results for GEM OS(R)1 in Canadian Foot and Ankle Fusion Study
Devices Orthopaedic
 HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2007
Cardium and InnerCool Complete $5 Million Commercial Financing to Support Launch of New Product Lines
Devices
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Oct 2007
InnerCool Licenses New Therapeutic for Potential Use in Stroke Patients
Devices Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 18 Jul 2007
FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Jul 2007
BioMimetic Therapeutics' Clinical Investigator Presents Positive Interim Data on U.S. and Canadian Foot and Ankle Clinical Trials
Devices Orthopaedic
 HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jun 2007
BioSET Announces Completion of $11 Million Financing to Support Clinical Trial of Synthetic Growth Factor for Spine Fusion
Devices Orthopaedic Venture Capital
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
Y's Therapeutics Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
First Patient Enrolled in RAPID MI-ICE Study Employing InnerCool's Endovascular Temperature Modulation Therapy for Heart Attack
Devices Cardiology
 HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Feb 2007
BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2007
Cardium and InnerCool Announce New External and Internal Patient Temperature Modulation Systems
Devices
 HSMN NewsFeed - 25 Jan 2007
BioMimetic Therapeutics Reports Positive Clinical Results Using GEM OS(R)1 to Treat Distal Radius Fractures
Devices Orthopaedic
 HSMN NewsFeed - 16 Jan 2007
Pharming Receives European Orphan Drug Designation
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
BioMimetic Therapeutics Announces Positive Results Using GEM OS1(TM) Bone Graft in Foot/Ankle Fusions
Devices Orthopaedic
 HSMN NewsFeed - 7 Dec 2006
Cardium's Generx Advances to Phase 3 Following Meeting With FDA
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Nov 2006
Cardium Announces Formation of Scientific Advisory Board
Devices Personnel
 HSMN NewsFeed - 13 Nov 2006
Treatment of Diabetic Foot Ulcers to Be Addressed at Upcoming American Heart Association Meeting
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 24 Oct 2006
Cardium Reports on Positive Effects of Hypothermia Following Heart Attack and Announces Clinical Study to Be Co-Sponsored by Swedish Cardiology Center
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Oct 2006
BioMimetic Therapeutics Receives FDA Approval that Expands Manufacturing Capacity for GEM 21S(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Sep 2006
Dr. Michael Morgan Reports on Benefits of InnerCool's Celsius Control System in Inducing Hypothermia During Aneurysm Surgery
Devices Neurosurgery
 HSMN NewsFeed - 14 Aug 2006
Cardium Acquires Excellarate Product Candidate for Chronic Diabetic Ulcers and Related Technology and Assets From Tissue Repair Company
Biopharmaceuticals Wound Care Acquisitions
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2006
Tigris Pharmaceuticals Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jun 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2006
Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2006
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2006
European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Feb 2006
Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets in Combination With Two Chemotherapeutic Agents
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2006
Recent Study Confirms REGRANEX Gel to be Effective Treatment of Diabetic Neuropathic Foot Ulcers
Biopharmaceuticals Wound Care
Return to NewsFeed  

 Additional items found! 40

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 40 additional stories matching:
DGF
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.